Monday, March 01, 2021 3:26:07 PM
Jack, here is the other post about DCVax-L and ATL-DC I posted. I included direct links. Please show me the hearsay & pumping:
Also, nsgmd5, if you can read between the lines, and you know where to look, you will see the obvious connections between: UCLA, NWBio, Merck, DCVax & Keytruda. Take a look at the ATL-DC + Keytruda trial Sponsors & Collaborators on the clinical trials.org site link below:
UCLA - Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Merck Sharp & Dohme Corp.
Phase One Foundation
Oncovir, Inc
https://clinicaltrials.gov/ct2/show/NCT04201873
Then take a look at who is the Phase One Foundation, and the money ($400,000) they gave to UCLA to conduct this study:
https://www.phaseonefoundation.org/latest-news/cancer-researchers-develop-immunebased-therapies-for-deadly-brain-tumors
Then, go to the above link and look for this paragragraph:
Then, touch the blue link in this paragraph, it says: “was developed by Liau”. This blue link will take you to this page:
https://newsroom.ucla.edu/releases/personalized-vaccine-increase-long-term-survival-glioblastoma
This page clearly shows you that the ATL-DC vaccine developed by Dr. Linda Liau is DCVax-L. It says the following:
Also, nsgmd5, if you can read between the lines, and you know where to look, you will see the obvious connections between: UCLA, NWBio, Merck, DCVax & Keytruda. Take a look at the ATL-DC + Keytruda trial Sponsors & Collaborators on the clinical trials.org site link below:
UCLA - Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Merck Sharp & Dohme Corp.
Phase One Foundation
Oncovir, Inc
https://clinicaltrials.gov/ct2/show/NCT04201873
Then take a look at who is the Phase One Foundation, and the money ($400,000) they gave to UCLA to conduct this study:
https://www.phaseonefoundation.org/latest-news/cancer-researchers-develop-immunebased-therapies-for-deadly-brain-tumors
Then, go to the above link and look for this paragragraph:
The funding will help open a clinical trial testing a combination treatment strategy using checkpoint inhibitors in conjunction with a personalized dendritic cell vaccine, which was developed by Liau at UCLA
Then, touch the blue link in this paragraph, it says: “was developed by Liau”. This blue link will take you to this page:
https://newsroom.ucla.edu/releases/personalized-vaccine-increase-long-term-survival-glioblastoma
This page clearly shows you that the ATL-DC vaccine developed by Dr. Linda Liau is DCVax-L. It says the following:
The vaccine, known as DCVax-L, uses a person’s own white blood cells to help activate the immune system to fight cancer
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
